Hematology-Oncology and Stem-Cell Transplantation Unit, Department of Hematology and Innovative Therapies, Istituto Nazionale Tumori - IRCCS - Fondazione 'G. Pascale', Napoli, Italy.
Hematology-Oncology and Stem-Cell Transplantation Unit, Department of Hematology and Innovative Therapies, Istituto Nazionale Tumori - IRCCS - Fondazione 'G. Pascale', Napoli, Italy.
Cytotherapy. 2018 Nov;20(11):1309-1323. doi: 10.1016/j.jcyt.2018.09.007. Epub 2018 Oct 22.
Dendritic cells (DCs) are bone marrow-derived immune cells that play a crucial role in inducing the adaptive immunity and supporting the innate immune response independently from T cells. In the last decade, DCs have become a hopeful instrument for cancer vaccines that aims at re-educating the immune system, leading to a potent anti-cancer immune response able to overcome the immunosuppressive tumor microenvironment (TME). Although several studies have indicated that DC-based vaccines are feasible and safe, the clinical advantages of DC vaccination as monotherapy for most of the neoplasms remain a distant target. Recently, many reports and clinical trials have widely used innovative combinatorial therapeutic strategies to normalize the immune function in the TME and synergistically enhance DC function. This review will describe the most relevant and updated evidence of the anti-cancer combinatorial approaches to boost the clinical potency of DC-based vaccines.
树突状细胞（DCs）是骨髓来源的免疫细胞，在诱导适应性免疫和独立于 T 细胞支持固有免疫反应方面发挥着关键作用。在过去的十年中，DCs 已成为癌症疫苗的一种有希望的手段，旨在重新教育免疫系统，导致能够克服免疫抑制性肿瘤微环境（TME）的强大抗肿瘤免疫反应。尽管有几项研究表明基于 DC 的疫苗是可行和安全的，但作为大多数肿瘤的单一疗法，DC 疫苗的临床优势仍然是一个遥远的目标。最近，许多报告和临床试验广泛使用创新的组合治疗策略来使 TME 中的免疫功能正常化，并协同增强 DC 的功能。这篇综述将描述增强基于 DC 的疫苗的临床疗效的最相关和最新的癌症联合治疗方法的证据。
